Last Updated: May 17, 2026

CLINICAL TRIALS PROFILE FOR YONDELIS

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Yondelis

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00060944 ↗	A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer	Completed	PharmaMar	Phase 2	2003-05-01	The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with types of advanced cancer referred to as liposarcoma or leiomyosarcoma.
NCT00060944 ↗	A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 2	2003-05-01	The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with types of advanced cancer referred to as liposarcoma or leiomyosarcoma.
NCT00070109 ↗	Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors	Completed	National Cancer Institute (NCI)	Phase 2	2008-01-01	This phase II trial is studying how well trabectedin works in treating young patients with recurrent or refractory soft tissue sarcoma or Ewing's family of tumors. Drugs used in chemotherapy such as trabectedin use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00070109 ↗	Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors	Completed	Children's Oncology Group	Phase 2	2008-01-01	This phase II trial is studying how well trabectedin works in treating young patients with recurrent or refractory soft tissue sarcoma or Ewing's family of tumors. Drugs used in chemotherapy such as trabectedin use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00072670 ↗	A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer	Completed	PharmaMar	Phase 2	2004-01-01	The purpose of this study is to evaluate safety and efficacy of trabectedin (ET-743) in adult male participants with advanced metastatic (spread of cancer cells from one part of the body to another) prostate cancer.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Yondelis

Condition Name

Chart
Table

Condition Name for Yondelis
Intervention	Trials
Soft Tissue Sarcoma	8
Sarcoma	8
Leiomyosarcoma	5
Ovarian Cancer	4
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Yondelis
Intervention	Trials
Sarcoma	23
Leiomyosarcoma	10
Liposarcoma	9
Ovarian Neoplasms	8
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Yondelis

Trials by Country

Map
Table

Trials by Country for Yondelis
Location	Trials
United States	218
Italy	100
Spain	17
Germany	16
France	13
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Yondelis
Location	Trials
California	12
Massachusetts	10
Texas	9
Pennsylvania	9
Ohio	9
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Yondelis

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Yondelis
Clinical Trial Phase	Trials
Phase 3	11
Phase 2	27
Phase 1/Phase 2	3
[disabled in preview]	5
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Yondelis
Clinical Trial Phase	Trials
Completed	31
Recruiting	8
Withdrawn	3
[disabled in preview]	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Yondelis

Sponsor Name

Chart
Table

Sponsor Name for Yondelis
Sponsor	Trials
PharmaMar	18
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	8
National Cancer Institute (NCI)	7
[disabled in preview]	9
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Yondelis
Sponsor	Trials
Other	52
Industry	41
NIH	7
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.